ArticleNPJ precision oncology2025
Artificial intelligence-driven prediction of lymph node metastasis in T1 esophageal squamous cell carcinoma using whole slide images.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Accurate prediction of lymph node metastasis (LNM) in T1 esophageal squamous cell cancer is critical for guiding treatment decisions after endoscopic submucosal dissection (ESD). We developed a deep learning-based artificial intelligence model using whole slide images (WSIs) to predict LNM and reduce overtreatment. The model was trained, validated, and internally tested on 160 surgically resected cases (72 LNM+, 88 LNM-) from 374 patients without prior ESD, achieving an AUC of 0.949 (95% CI: 0.912-0.986) on internal test. Further validation was performed on an external ESD cohort comprising clinically high-risk cases with invasion depths from MM to SM2. The model attained an accuracy of 90.1%, sensitivity of 81.8%, specificity of 91.4%, and an F1-score of 69.2%. It correctly classified 90.1% of samples, with a negative predictive value (NPV) of 96.9%. The high NPV and specificity underscore the model's utility in minimizing overtreatment while preserving diagnostic accuracy in high-risk T1 esophageal cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.